Abstract
AbstractSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged late in 2019 and caused the coronavirus disease 2019 (COVID-19) pandemic that has so far claimed approximately 20 million lives. Vaccines were developed quickly, became available in the end of 2020, and had a tremendous impact on protection from SARS-CoV-2 mortality but with emerging variants the impact on morbidity was diminished. Here I review what we learned from COVID-19 from a vaccinologist’s perspective.
Publisher
Springer Science and Business Media LLC
Subject
Immunology,Immunology and Allergy
Reference161 articles.
1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J et al (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382:727–733
2. https://virological.org/t/novel-2019-coronavirus-genome/319. virological.org. Accessed 1/17/2023.
3. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team (2020) The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) - China, 2020. China CDC Wkly 2:113–122
4. Yavarian J, Shafiei-Jandaghi NZ, Sadeghi K, Shatizadeh Malekshahi S, Salimi V, Nejati A et al (2020) First cases of SARS-CoV-2 in Iran, 2020: case series report. Iran J Public Health 49:1564–1568
5. Cereda D, Manica M, Tirani M, Rovida F, Demicheli V, Ajelli M et al (2021) The early phase of the COVID-19 epidemic in Lombardy. Italy Epidemics 37:100528
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献